PMID- 32869263
OWN - NLM
STAT- MEDLINE
DCOM- 20210622
LR  - 20211204
IS  - 2543-6031 (Electronic)
IS  - 2451-4934 (Linking)
VI  - 88
IP  - 4
DP  - 2020
TI  - The incidence of mTOR marker in tracheal adenoid cystic carcinoma by 
      immunohistochemical staining.
PG  - 305-312
LID - 10.5603/ARM.a2020.0120 [doi]
AB  - INTRODUCTION: There is an association between the activation of mammalian target 
      of rapamycin (mTOR) signaling and aggressive tumor growth in multiple forms of 
      cancer,including adenoid cystic carcinoma (ACC). ACCs are uncommon yet a 
      malignant form of neoplasms that arises within the secretory glands. Therefore, 
      the aim of this study was to investigate the increase of mTOR in the ACC tumors 
      in order to survey the possibility of treating these tumors with mTOR inhibitors. 
      MATERIAL AND METHODS: Samples from known cases of the lung and tracheal ACC were 
      retrievedfrom the archives of the pa-thology department of Masih Daneshvari 
      hospital, and immunohistochemical (IHC) staining for mTOR was performed on them. 
      After preparation of the blocks with specific antibodies, tumor cells with 
      cytoplasmic and/or nuclear expression of mTOR were considered as positive cells 
      by applying a specific scoring method introduced in this study. RESULTS: The 
      paraffin blocks of 26 patients were surveyed and the IHC marker of mTOR was 
      positive in the tumors of 10 patients (38.5%). Out of 10 mTOR positive cases, 5 
      were females and 5 were males. The primary site of the surveyed tumors was the 
      trachea and bronchus in 12 cases (46%), salivary glands in 7 individuals (27%), 
      and lung tissue in 7 cases (27%), and there was no significant correlation 
      between the primary site of the ACC tumors and the existence of the mTOR markers 
      in them (P = 0.67). From all cases, 13 patients (50%) had cribriform and tubular 
      cells without solid components, 9 cases (34.6%) had cribriform and tubular with 
      less than 30% of solid components, and 4 cases (15.4%) had cribriform and tubular 
      cells with more than 30% of solid com-ponents. There was no significant 
      difference between the morphologies and the existence of mTOR markers in them (P 
      = 0.741). CONCLUSIONS: As the incidence of mTOR markers is seen in patients with 
      tracheal ACC, evaluation and scoring of mTOR in these persons can be helpful as 
      further studies can distinguish the use of it in the treatment of the disease. .
FAU - Pourabdollah Toutkaboni, Mihan
AU  - Pourabdollah Toutkaboni M
AD  - Pediatric Respiratory Diseases Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Farahani, Mehrdad
AU  - Farahani M
AD  - Department of Interventional Pulmonology, Tracheal Diseases Research Center, 
      National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Sadegh, Abdolreza
AU  - Sadegh A
AD  - Pediatric Respiratory Diseases Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Kiani, Arda
AU  - Kiani A
AD  - Tracheal Diseases Research Center, National Research Institute of Tuberculosis 
      and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Sadr, Makan
AU  - Sadr M
AD  - Virology Research Center, National Research Institute of Tuberculosis and Lung 
      Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Taghavi, Kimia
AU  - Taghavi K
AD  - Chronic Respiratory Diseases Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran.
FAU - Abedini, Atefeh
AU  - Abedini A
AUID- ORCID: 0000-0002-3119-9839
AD  - Chronic Respiratory Diseases Research Center, National Research Institute of 
      Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, 
      Tehran, Iran. dr.abedini110@sbmu.ac.ir.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Adv Respir Med
JT  - Advances in respiratory medicine
JID - 101697329
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Adenoid Cystic/*metabolism/pathology
MH  - Female
MH  - Head and Neck Neoplasms/*metabolism/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Staining and Labeling
MH  - TOR Serine-Threonine Kinases/*analysis/metabolism
MH  - Tracheal Neoplasms
OTO - NOTNLM
OT  - adenoid cystic carcinoma
OT  - immunohistochemistry
OT  - mTOR
EDAT- 2020/09/02 06:00
MHDA- 2021/06/23 06:00
CRDT- 2020/09/02 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/27 00:00 [accepted]
PHST- 2020/03/26 00:00 [revised]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2021/06/23 06:00 [medline]
AID - VM/OJS/J/67109 [pii]
AID - 10.5603/ARM.a2020.0120 [doi]
PST - ppublish
SO  - Adv Respir Med. 2020;88(4):305-312. doi: 10.5603/ARM.a2020.0120.